Page 50 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 50
Chapter 3
Results
The search yielded 9,960 records after removing duplicates; 290 concerned studies on NHL and interim FDG-PET, the other 9,670 records were excluded because they did not report on NHL or I-PET. 85/290 were potentially eligible and full- text articles were retrieved. After checking detailed inclusion and exclusion criteria we included 20 eligible studies in the qualitative systematic review; 19 out of 20 were eligible for the HRs evaluations and 18 out of 20 for the HSROC analyses (Fig. 1).
Fig. 1 PRISMA flow diagram.
*Records refer to the title and abstract screening of the search results
†Full-text articles refer to the full-text assessment of the selected articles from the title and abstract screening phase.
Abbreviations: I-PET= interim 18F-FDG positron emission tomography, FLT= Fluorothymidine, DLBCL= diffuse large B-cell lymphoma, EoT-PET= end-of-treatment 18F-FDG positron emission tomography, HR= hazard ratio, HSROC= hierarchical summary receiver operating curve
48
